Mantle Cell Lymphoma
News
Rituximab maintenance halves MCL death risk after ASCT
The rate of 4-year event-free survival was 79% for patients maintained on rituximab vs. 61% for those on observation alone.
News
Plerixafor doesn’t overcome HPC failure in R-hyperCVAD for mantle cell lymphoma
Even with plerixafor, HPC failure was more common when mantle cell lymphoma patients received R-hyperCVAD.
News
FDA grants priority review of acalabrutinib for second-line treatment of MCL
Acalabrutinib for treatment of patients with mantle cell lymphoma has been granted priority review by the FDA.
News
IMiD/Anti-CD20 combo induces complete responses in r/r NHL
Lugano, Switzerland – A combination of obinutuzumab (Gazyva) and the experimental immunomodulatory agent CC-122 showed “clinically meaningful”...
Conference Coverage
Chemo-free induction in MCL keeps getting better
Lugano, Switzerland –
Conference Coverage
Bendamustine plus rituximab may have edge for treating indolent NHL, MCL
CHICAGO – Bendamustine plus rituximab may have some advantages for treatment-naive patients with indolent non-Hodgkin lymphoma or mantle cell...
Conference Coverage
Hitting BTK, PI3K pays off in B-cell malignancies
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
News
Liposomes boost bortezomib efficacy
Liposomes might be able to boost efficacy and reduce side effects of bortezomib.
Conference Coverage
Early allo SCT advised for high-risk mantle cell lymphoma
High-risk patients with mantle cell lymphoma who have a matched related donor have a better chance for survival if they do not delay allogeneic...
Conference Coverage
ALC/AMC prognostic in mantle cell lymphoma
The peripheral blood absolute lymphocyte-to-monocyte ratio (ALC/AMC) was prognostic for overall survival in mantle cell lymphoma patients who have...